Form 8-K - Current report:
SEC Accession No. 0001104659-24-003852
Filing Date
2024-01-16
Accepted
2024-01-16 06:16:14
Documents
12
Period of Report
2024-01-12
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm243112d1_8k.htm   iXBRL 8-K 24563
  Complete submission text file 0001104659-24-003852.txt   197413

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tbph-20240112.xsd EX-101.SCH 3021
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20240112_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20240112_pre.xml EX-101.PRE 22363
6 EXTRACTED XBRL INSTANCE DOCUMENT tm243112d1_8k_htm.xml XML 3335
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 24533559
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)